Close

Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. HCP
6. SPY
7. BSX
8. PI
9. CNMD
10. NOW


Go back to Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s

Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108

October 26, 2016 9:22 AM EDT

Stifel analyst Adam Walsh trimmed his price target on Vertex (NASDAQ: VRTX) to $108.00 (from $109.00) but maintained a Buy rating as the triple combo moves forward.

Walsh commented, "At last, Vertex outlined the path forward for its triple combo regimens, removing an overhang on the stock as the competitive landscape heats up with Galapagos/Abbvie (not... More

Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update

October 26, 2016 6:51 AM EDT

BMO Capital analyst Do Kim bumped his price target on Vertex (NASDAQ: VRTX) to $88.00 (from $87.00) following results and the triple combo update but maintained a Market Perform rating.

Kim commented, " Vertex's 3Q16 was generally in line with expectations, as prior comments and revised... More